Tag Archives: mygn

Myriad Genetics Soars On CMS Reimbursement Increase

Gene-testing company Myriad Genetics (MYGN) jumped to a five-year high in morning trading in the stock market today after it revealed late Tuesday that the U.S. government is paying a heftier reimbursement for its main test than previously feared. The news was the latest twist in a saga that started late last year, when the Center for Medicare & Medicaid Services said it would pay $1,438.14 per test for the BRCA 1 and 2 genes, which are associated

Myriad Stock Tumbles After Court Allows Rival To Sell

Myriad Genetics (MYGN) stock tumbled in early trading on the stock market today after a court late Monday denied it a preliminary injunction against a rival. Myriad has been trying to stop the entry of rival versions of its BRACAnalysis test for genetic susceptibility to breast cancer, ever since the Supreme Court invalidated some of its patents last year on the basis that genes are unpatentable. This particular case involved privately held Ambry

Myriad Price Cut Reflects Changing Gene-Test Industry

The genetic-testing industry has come under the microscope again after Myriad Genetics’ breast-cancer gene test got a big reimbursement cut from the federal government, adding pressure to a field whose 2014 outlook is cloudy. On Dec. 27, the Center for Medicare & Medicaid Services (CMS) said that starting Jan. 1 it will pay $1,438.14 for Myriad ‘s (MYGN) test for the BRCA 1 and 2 genes, as well as another test for the BRCA 1 gene alone. Earlier it